Erucic Acids

cis-13-Docosenoic Acids. 22-Carbon monounsaturated, monocarboxylic acids.

Also Known As:

Brassidic Acids; Acids, Brassidic; Acids, Docosenoic; Acids, Erucic; Docosenoic Acids

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Monounsaturated Fatty Acids: 676
      - Erucic Acids: 5
        erucic acid: 81
        Lorenzo's oil: 59
        trierucate: 16
        erucyl amide: 3
        erucylphosphohomocholine ErPC3: 3
        cetoleic acid: 2
        (Z)-N-(2-hydroxyethyl) docos-13-enamide: 1
        N,N-bis(2-chloroethyl)docos-13-enamide: 1
        9-((Z)-13-docosenyl)adenine
        Erucic acid anilide
        erucyl bis(hydroxyethyl) methylammonium chloride
        erucyl bis(hydroxymethyl)methylammonium
        N-hydroxysuccinimide erucic acid

Experts

1.	Beretta, Laura: 1 article (08/2013)
2.	Hazim, Antonious: 1 article (08/2013)
3.	He, Ying: 1 article (08/2013)
4.	Kim, Do-Young: 1 article (08/2013)
5.	Muir, Kyle: 1 article (08/2013)
6.	Peyressatre, Marion: 1 article (08/2013)
7.	Song, Xiaoling: 1 article (08/2013)
8.	Brasky, Theodore M: 1 article (01/2012)
9.	Lampe, Johanna W: 1 article (01/2012)
10.	Patterson, Ruth E: 1 article (01/2012)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2013 - "This integrative proteomic and lipidomic study from mouse to human and from liver to blood identified the following disease signatures: (i) an HCC signature: upregulated hepatic scd1/scd2, fads2, and acsl5:acsl1 ratio, elevated vaccenic and erucic acids, and reduced margaric and linoleic acids in both liver and plasma; (ii) a NASH signature that correlates with tumor burden: upregulated hepatic elovl6, elevated oleic, adrenic, and osbond acids, and reduced cervonic acid in liver and plasma; and (iii) a NASH signature: reduced hepatic and circulating lignoceric and eicosapentaenoic acids. "
2.	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 09/09/1993 - "In this open trial we found no evidence of a clinically relevant benefit from dietary treatment with oleic and erucic acids ("Lorenzo's oil") in patients with adrenomyeloneuropathy." 09/09/1993 - "A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy."
3.	Obesity 07/01/2008 - "Considering the proposed preventive effect of nervonic acid on obesity- and diabetes-related coronary risk factors, the content of its precursors (oleic, 11-eicosenoic and 13-docosenoic acids) was measured in liver and plasma phospholipids and triglycerides, brain and spleen phospholipids, and adipose tissue lipids of fed or overnight fasted control and hereditarily diabetic Goto-Kakizaki female rats, as well as fed streptozotocin-induced diabetic female rats. "
4.	Lipidoses 01/01/1981 - "Heart lipidosis induced by short-term feeding of cis- or trans-docosenoic acids in weanling or 7-week-old rats."
5.	Breast Neoplasms (Breast Cancer) 01/01/2012 - "Intake of total MUFAs (highest vs. lowest quintile: HR = 1.61, 95% CI: 1.08-2.38, P trend = 0.02), particularly myristoleic and erucic acids, was associated with increased breast cancer risk. "

Related Drugs and Biologics

1.	Linoleic Acids
2.	Acids
3.	Lorenzo's oil
4.	Triglycerides (Triacylglycerol)
5.	Streptozocin (Streptozotocin)
6.	Phospholipids (Phosphatides)
7.	Lipids
8.	nervonic acid